Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Q3 2021 Earnings Presentation
19 slides from Arcticzymes Technologies Asa's earnings presentation, 2021
Slide 1: ArcticZymes Technologies
A ArcticZymes Technologies
Slide 2: Agenda
Agenda 1 Highlights - Q3 2021 2 Business Update 3 Financials 4 Outlook 2021
Slide 3: Highlights
Highlights
Slide 4: Highlights Q3 2021
Highlights Q3 2021 Business is returning to normal. AZT is back on the road Executing on Quarterly non- Best quarterly sales strategic growth coronavirus performance for initiatives -related sale Therapeutics Intensifying M&A 89% contribution 12.6 MNOK process 2nd best quarter for Advance prototypes
Slide 5: Business Update
Business Update
Slide 6: Business Updates: Therapeutics (Biomanufacturing)
Business Updates Commercial Segment Sales Therapeutics Research & (Biomanufacturing) Diagnostics ✓ Highest quarterly sales performance 12.6 MNOK ✓ Research and Diagnostics contribution to Q3 sales ✓ 49% contribution to total Q3 sales were 24% and 27%, respectively ✓ Customer activities mostly return
Slide 7: Business Updates: Coronavirus-related sales
Business Updates Coronavirus-related sales 11% contribution of total Q3 sales Decline in coronavirus-related sales is directly linked to fall in demand for coronavirus testing Expect recurring business to continue but with progressively smaller orders Still attracting new opportunities - multiplex t
Slide 8: Business Update: Innovations
Business Update Innovations Four advanced prototype enzymes available to customers prior to launch in Q4 2021/Q1 2022 Dual Splint Ligase Heat-tolerant Duplex-Specific Nuclease (new DNase) High quality MMLV Reverse Transcriptase High Concentration IsoPolTM BST+ DNA polymerase M-SAN ELISA pilot produc
Slide 9: Business Update: Operations
Business Update Operations New production facilities progressing according to plan Infrastructure changes completed Equipment is being unpacked, undergoing qualification and Unpacking of new fermenter verification in accordance with ISO13485 requirements and cGMP guidelines Expect relocation to new
Slide 10: Business Updates: Strategic Growth Initiatives
Business Updates Strategic Growth Initiatives AZT is committed to execute on its strategic growth initiatives Organic growth Establishing a laboratory in Oslo focusing on applications development Rationale: Oslo has a talent pool of commercially experienced application scientists Expect to be operat
Slide 11: Financials
Financials
Slide 12: ArcticZymes Sales Q3 2021
ArcticZymes Sales Q3 2021 Therapeutics picking up speed Sales per segment 50 000 Sales increase of 31% compared to same Amounts in NOK 1.000' quarter last year 45 000 Currency had negative impact on underlying 40 000 Therapeutics (SAN) sales growth 35 000 Research and Diagnostics Therapeutics segmen
Slide 13: ArcticZymes Sales Q3 2021: Covid-19 impact
ArcticZymes Sales Q3 2021 Covid-19 impact continues to slow down Estimated Coronavirus related sales 18 000 Amounts in NOK 1.000' 16 000 14 000 12 000 Sales in TNOK 10 000 8 000 6 000 4 000 2 000 - Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 13
Slide 14: 12 Month rolling average quarterly sales
12 Month rolling average quarterly sales Trend is positive for Q3 2021 Amounts in NOK 1.000' 35 000 30 000 Sales development 25 000 Sales development ex Covid-19 20 000 15 000 10 000 5 000 - Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 14
Slide 15: Profitability and expenses
Profitability and expenses Investments in organic growth influences our figures Amounts in NOK 1.000' 45 000 40 000 Sales 31% increase in sales (MNOK 25.6 vs 19.5) EBITDA 35 000 EBITDA increased by 1.9 MNOK (MNOK 9.0 vs 7.1) 30 000 Expenses increased by 3.3 MNOK 25 000 Increase in personnel as we in
Slide 16: Cash Flow and Changes in cash
Cash Flow 9 MNOK invested in new premises Cash position 200 000 Amounts in NOK 1.000' 90 000 180 000 80 000 Net Cash 160 000 70 000 Changes in Cash 140 000 60 000 120 000 Changes in cash 50 000 Net Cash 100 000 40 000 80 000 30 000 60 000 20 000 40 000 20 000 10 000 0 0 Q1 2020 Q2 2020 Q3 2020 Q4 20
Slide 17: Outlook
Outlook
Slide 18: Outlook 2021: Financial guidance
Outlook 2021 Financial guidance Quarterly Rolling 12 Month Sales 140 Last quarter - provided guidance with an annual sales revenue target of 120 MNOK in 2021 120 Annual Revenue Target 2021 Last 12 month revenues (MNOK) AZT upholds this guidance 100 Longer-term growth is expected due to: 80 Momentum
Slide 19: Thank you Q&A Session
Thank you Q&A Session arcticzymes.com
ArcticZymes Technologies — Q3 2021 Earnings Presentation on 6ix